Evidence map›Paper›PMID 26284612›Full record

ArticleLeukemia & lymphoma2016

Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.

Beata Holkova, Maciej Kmieciak, Prithviraj Bose, Victor Y Yazbeck, Paul M Barr, Mary Beth Tombes, Ellen Shrader, Caryn Weir-Wiggins, April D Rollins, Erin M Cebula and 10 more

Open access · greenAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Genetic alterations and their clinical implications in DLBCL.Nature reviews. Clinical oncology · 2019
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Beata Holkovaa Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .
Maciej Kmieciaka Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .
Prithviraj Bosec University of Texas MD Anderson Cancer Center , Houston , TX , USA .
Victor Y Yazbecka Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .
Paul M Barrd James P. Wilmot Cancer Center, University of Rochester , Rochester , NY , USA .
Mary Beth Tombesa Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .
Ellen Shradera Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .
Caryn Weir-Wigginsa Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .
April D Rollinsa Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .
Erin M Cebulad James P. Wilmot Cancer Center, University of Rochester , Rochester , NY , USA .
Emily Pierced James P. Wilmot Cancer Center, University of Rochester , Rochester , NY , USA .
Megan Herrd James P. Wilmot Cancer Center, University of Rochester , Rochester , NY , USA .
Heidi Sankalaa Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .
Kevin T Hogana Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .
Wen Wane Department of Biostatistics , Virginia Commonwealth University , Richmond , VA , USA .
Changyong Fengd James P. Wilmot Cancer Center, University of Rochester , Rochester , NY , USA .
Derick R Petersonf Department of Biostatistics and Computational Biology , University of Rochester , Rochester , NY , USA .
Richard I Fisherg Fox Chase Cancer Center , Temple Health , Philadelphia , PA , USA .
Steven Granta Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .
Jonathan W Friedbergd James P. Wilmot Cancer Center, University of Rochester , Rochester , NY , USA .
Virginia Commonwealth University · USUniversity of Rochester · USFox Chase Cancer Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Keri R Maher · 1985 to 2026
$51.0M
Center for Clinical and Translational ResearchUL1TR000058 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2012 to 2015
$12.5M
SPORE in LymphomaP50CA130805 · NCI · UNIVERSITY OF ROCHESTER · PI FISHER, RICHARD I · 2008 to 2012
$11.7M
NF-kappaB Inhibitors and Differentiation-Inducers in LeukemiaR01CA093738 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GRANT, STEVEN · 2002 to 2011
$2.4M
Checkpoint Abrogation and MEK 1/2 Inhibition in MyelomaR01CA100866 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GRANT, STEVEN · 2003 to 2013
$2.2M
Targeting AML with PI3K/AKT inhibitors and BH3-mimeticsR01CA167708 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GRANT, STEVEN · 2013 to 2017
$1.6M
Flavopiridol / Bortezomib in Myeloma / B-Cell NeoplasmsR21CA110953 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GRANT, STEVEN · 2004 to 2008
$483k
NCATS NIH HHS UL1 TR000058NCATS NIH HHS UL1TR000058NCI NIH HHS P30 CA006927NCI NIH HHS P30 CA016059NCI NIH HHS P50 CA130805NCI NIH HHS R01 CA093738NCI NIH HHS R01 CA100866NCI NIH HHS R01 CA167708NCI NIH HHS R01 CA93738NCI NIH HHS R21 CA110953
6 · The paper itself

Abstract

A phase 1 study with carfilzomib and vorinostat was conducted in 20 B-cell lymphoma patients. Vorinostat was given orally twice daily on days 1, 2, 3, 8, 9, 10, 15, 16, and 17 followed by carfilzomib (given as a 30-min infusion) on days 1, 2, 8, 9, 15, and 16. A treatment cycle was 28 days. Dose escalation initially followed a standard 3 + 3 design, but adapted a more conservative accrual rule following dose de-escalation. The maximum tolerated dose was 20 mg/m2 carfilzomib and 100 mg vorinostat (twice daily). The dose-limiting toxicities were grade 3 pneumonitis, hyponatremia, and febrile neutropenia. One patient had a partial response and two patients had stable disease. Correlative studies showed a decrease in NF-κB activation and an increase in Bim levels in some patients, but these changes did not correlate with clinical response.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkersCombined Modality TherapyCytokinesDrug MonitoringDrug Resistance, NeoplasmFemaleHumansHydroxamic AcidsLymphoma, B-CellMaleMiddle AgedNeoplasm Recurrence, LocalOligopeptidesBiomarkerscarfilzomibCytokinesHydroxamic AcidsOligopeptidesVorinostatCarfilzomiblymphomaphase 1 clinical trialvorinostat

Identifiers

PMID26284612
PMCPMC4798896
OpenAlexW1671254148

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.